Tadekinig alfa (IL-18BP) for Hemophagocytic Lymphohistiocytosis

University of Pennsylvania, Philadelphia, PA
Hemophagocytic Lymphohistiocytosis+2 More ConditionsTadekinig alfa (IL-18BP) - Drug
All Sexes

Study Summary

This trial is testing the safety of using an investigational drug to treat CAR T cell related CRS and HLH-like syndrome.

Eligible Conditions
  • Hemophagocytic Lymphohistiocytosis
  • Cytokine Release Syndrome

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase < 1

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 28 days

28 days
Evaluate preliminary safety and feasibility of administering investigational rescue therapies for the treatment of CAR T cell related CRS and CRHLS.

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

Tadekinig alfa
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Tadekinig alfa (IL-18BP) · No Placebo Group · Phase < 1

Tadekinig alfa
Experimental Group · 1 Intervention: Tadekinig alfa (IL-18BP) · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 28 days

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
1,899 Previous Clinical Trials
41,218,083 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Are medical practitioners currently enrolling participants for this experiment?

"According to clinicaltrials.gov, the recruitment phase of this study is ongoing with postings appearing as early April 17th 2022 and the most recent update being on July 5th 2022." - Anonymous Online Contributor

Unverified Answer

How many participants have been recruited to join this clinical trial?

"Affirmative. Clinicaltrials.gov specifics that this experiment is recruiting, with the first post dating back to April 17th 2022 and the most recent update occurring on July 5th 2022. This research necessitates 10 volunteers from 1 location." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.